<DOC>
	<DOCNO>NCT02964715</DOCNO>
	<brief_summary>Non-Alcoholic Fatty Liver Disease ( NAFLD ) common patient type 2 diabetes . Empagliflozin , FDA-approved oral medication use treat type 2 diabetes , show reduce production deposition fat liver animal experiment . There little publish evidence Asian patient type 2 diabetes . The investigator design pilot study determine use empagliflozin 6 month patient type 2 diabetes improve scan , blood marker biopsy feature NAFLD .</brief_summary>
	<brief_title>The Effect Empagliflozin NAFLD Asian Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Empagliflozin , FDA-approved SGLT2 ( Sodium glucose transporter 2 ) inhibitor use treat type 2 diabetes , show reduce hepatic de novo lipogenesis hepatic steatosis animal model . There little publish evidence Asian patient type 2 diabetes . The investigator design open label proof concept trial determine use empagliflozin 6 month patient type 2 diabetes improve biomarkers histological feature biopsy proven NAFLD . Hypotheses 1 . 6 month empagliflozin result improve histology liver biopsy type 2 dm patient NAFLD 2.6 month empagliflozin result change liver enzymes , adipocytokines FGF level type 2 dm patient NAFLD 3.6 month empagliflozin result improve liver stiffness measurement type 2 dm patient NAFLD Study protocol This prospective open-label proof-of-concept study . The investigator plan recruit 25 Asian patient biopsy-proven NASH type 2 diabetes commence empagliflozin 25 mg daily 6 month . Upon recruitment clinical information obtain via interview use structure questionnaire . Anthropometric measurement obtain baseline 6 month . A repeat liver biopsy perform 6 month empagliflozin therapy . MRI fibroscan liver conduct baseline 6 month . Fasting blood sample draw glucose , insulin , c-peptide , triglyceride , HDL , LDL , total cholesterol , NEFA ( non-esterified fatty acid ) , HbA1c , liver function test ( include albumin , AST , ALT , gamma GT , uric acid , inflammatory marker , FGF ( fibroblast growth factor ) biomarkers baseline 6 month . Patients review physician 1 month 6 month development potential adverse event empagliflozin therapy . Patients instructed make significant change diet lifestyle 6 month order ass full effect intervention possible confounding factor .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>biopsy proven NASH Type 2 DM HbA1c : &gt; 6.5 % BMI &lt; 45kg/m2 Any antidiabetic agent except SGLT2 inhibitor , TZDs ( thiazolidinediones ) , DPP4 ( Dipeptidyl peptidase4 ) inhibitor GLP1 RAs ( Glucagonlike Peptide 1Receptor Agonists ) eGFR &lt; 45 ml/min structural functional urogenital abnormality , predispose urogenital infection Investigational product use last 6 month SGLT2 inhibitor , TZD , DPP4 inhibitor GLP1 RA use within past 6 month DKA ( Diabetic Ketoacidosis ) HHS ( Hyperosmoloar Hyperglycaemic Syndrome ) within last 6 month Pregnancy Presence major contraindication magnetic resonance imaging ( cardiac pacemaker , claustrophobia , foreign body implant medical device ferromagnetic property ) . Liver cirrhosis Type 1 diabetes Severe uncorrected insulin insufficiency Significant alcohol intake HIV infection Use Traditional Chinese Medication alternative therapy Coexisting cause chronic liver disease chronic viral hepatitis ( B &amp; C ) , autoimmune liver disease , hemochromatosis , Wilson 's etc . Use medication associate steatosis eg . Methotrexate , anticonvulsant , antiretroviral therapy etc . h/o stroke Steroid therapy Endogenous Cushing 's Familial hypertriglyceridemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>